Enhanced Recovery Protocol Ups Outcomes in Colon, Rectal Sx

Share this content:
Enhanced Recovery Protocol Ups Outcomes in Colon, Rectal Sx
Enhanced Recovery Protocol Ups Outcomes in Colon, Rectal Sx

MONDAY, July 10, 2017 (HealthDay News) -- For patients undergoing colon and rectal surgery, an enhanced recovery protocol (ERP) is associated with improved outcomes, according to clinical practice guidelines published in the August issue of Diseases of the Colon & Rectum.

Joseph C. Carmichael, M.D., from the University of California, Irvine School of Medicine, and colleagues from the American Society of Colon and Rectal Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons used the best available evidence to develop guidelines on enhanced recovery after colon and rectal surgery.

The researchers note that an ERP, which is a set of standardized perioperative procedures and practices, is associated with a reduction in overall complications, length of stay, and health care costs, and an improvement in patient satisfaction. Improved outcomes are seen in association with ERPs, regardless of whether patients undergo laparoscopic or open surgery. In order to continue to improve quality, ERPs require a continued audit process. Based on one retrospective review of eight years of compliance, the strongest predictors of shorter length of stay were identified as no nasogastric tube, early mobilization, early oral nutrition, early removal of epidural and urinary catheter, and nonopioid analgesia.

"The ultimate judgment regarding the propriety of any specific procedure must be made by the physician in light of all of the circumstances presented by the individual patient," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths